Slack B E, Breu J, Muchnicki L, Wurtman R J
Department of Pathology and Laboratory Medicine, Boston University School of Medicine, 85 East Newton Street, Rm. 1007, Boston MA 02118, USA.
Biochem J. 1997 Oct 1;327 ( Pt 1)(Pt 1):245-9. doi: 10.1042/bj3270245.
The amyloid precursor protein (APP) of Alzheimer's disease is a transmembrane protein that is cleaved by an uncharacterized enzyme known as alpha-secretase within its extracellular/intraluminal domain after the activation of guanine nucleotide-binding protein-coupled receptors linked to phosphoinositide hydrolysis. The secretory process results in the release of large soluble derivatives of APP (APPs), and, when elicited by muscarinic receptor activation, exhibits both protein kinase C (PKC)-dependent and tyrosine phosphorylation-dependent components [Slack, Breu, Petryniak, Srivastava and Wurtman (1995) J. Biol. Chem. 270, 8337-8344]. In this report we examine the regulation of the release of APPs by epidermal growth factor (EGF) receptors, which possess intrinsic tyrosine kinase activity, and are coupled to a variety of effectors including phosphoinositide-specific phospholipase Cgamma. In A431 cells, EGF caused time-dependent and dose-dependent increases in the formation of inositol phosphates in cultures prelabelled with myo--3H-inositol, and in the release of APPs into the culture medium; the two responses exhibited similar time courses and EC50 values for EGF. Concomitant with these effects, there were concentration-dependent (3-300 ng/ml) increases in the phosphorylation of tyrosine residues in several proteins, including the EGF receptor itself. The specific PKC antagonist GF 109203X decreased the effect of EGF by approx. 35% at a concentration that abolished the stimulation of the release of APPs by the PKC activator PMA. Tyrphostin AG 1478, an inhibitor of EGF receptor tyrosine kinase, abolished the EGF-induced release of APPs. These results demonstrate that in A431 cells, activation of the EGF receptor stimulates alpha-secretase activity by a mechanism that is partly dependent on PKC activity.
阿尔茨海默病的淀粉样前体蛋白(APP)是一种跨膜蛋白,在与磷酸肌醇水解相关的鸟嘌呤核苷酸结合蛋白偶联受体激活后,在其细胞外/管腔内结构域被一种未知的酶(称为α-分泌酶)切割。分泌过程导致APP的大的可溶性衍生物(APPs)释放,当由毒蕈碱受体激活引发时,表现出蛋白激酶C(PKC)依赖性和酪氨酸磷酸化依赖性成分[斯莱克、布雷乌、佩特里尼亚克、斯里瓦斯塔瓦和伍特曼(1995年)《生物化学杂志》270,8337 - 8344]。在本报告中,我们研究了具有内在酪氨酸激酶活性并与多种效应器(包括磷酸肌醇特异性磷脂酶Cγ)偶联的表皮生长因子(EGF)受体对APPs释放的调节。在A431细胞中,EGF导致用肌醇 - 3H - 肌醇预标记的培养物中肌醇磷酸形成以及APPs释放到培养基中的时间依赖性和剂量依赖性增加;这两种反应对EGF表现出相似的时间进程和EC50值。伴随这些效应,包括EGF受体本身在内的几种蛋白质中酪氨酸残基的磷酸化出现浓度依赖性(3 - 300 ng/ml)增加。特异性PKC拮抗剂GF 109203X在消除PKC激活剂PMA对APPs释放的刺激的浓度下,使EGF的作用降低约35%。EGF受体酪氨酸激酶抑制剂酪氨酸磷酸化抑制剂AG 1478消除了EGF诱导的APPs释放。这些结果表明,在A431细胞中,EGF受体的激活通过部分依赖PKC活性的机制刺激α-分泌酶活性。